InvestorsHub Logo
Followers 16
Posts 3999
Boards Moderated 0
Alias Born 01/12/2004

Re: None

Tuesday, 12/31/2019 11:48:49 AM

Tuesday, December 31, 2019 11:48:49 AM

Post# of 660
"Results showed that AXS-07 met the two regulatory, co-primary endpoints and significantly improved migraine pain and most trouble symptoms as compared to placebo. The candidate also met the key secondary endpoint, demonstrating statistically significant superiority to the active comparator rizatriptan on sustained freedom from migraine pain. A greater percentage of patients achieved pain freedom and absence of most bothersome symptom with AXS-07 after two hours of dosing as compared to placebo. The candidate was safe and well tolerated in the trial."

https://finance.yahoo.com/news/axsomes-axsm-migraine-drug-meets-142602900.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News